Literature DB >> 17420214

Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.

Ilya Lebeau1, Graciela Andrei, Marcela Krecmerová, Erik De Clercq, Antonin Holy, Robert Snoeck.   

Abstract

Murine polyomavirus and simian virus 40 were used to evaluate the potencies of the compounds of three classes of acyclic nucleoside phosphonates: (i) the original HPMP (3-hydroxy-2-phosphonomethoxypropyl) and PME (2-phosphonomethoxyethyl) derivatives, (ii) the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidine (DAPy) derivatives, and (iii) a new class of HPMP derivatives containing a 5-azacytosine moiety. The last class showed the highest activities and selectivities against both polyomaviruses.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17420214      PMCID： PMC1891398          DOI： 10.1128/AAC.01422-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro.

Authors:  Karl Y Hostetler; Steffney Rought; Kathy A Aldern; Julissa Trahan; James R Beadle; Jacques Corbeil
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

Review 2.  Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir.

Authors:  S Osorio; R de la Cámara; N Golbano; E Marti; C G Fedele; S Nieto; R Manzanares; J M Fernández-Rañada
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

3.  Activities of various compounds against murine and primate polyomaviruses.

Authors:  G Andrei; R Snoeck; M Vandeputte; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.

Authors:  James R Beadle; Caroll Hartline; Kathy A Aldern; Natalie Rodriguez; Emma Harden; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults.

Authors:  Abhay Vats; Ron Shapiro; Parmjeet Singh Randhawa; Velma Scantlebury; Acar Tuzuner; Malika Saxena; Michael L Moritz; T James Beattie; Thomas Gonwa; Michael D Green; Demetrius Ellis
Journal:  Transplantation       Date:  2003-01-15       Impact factor: 4.939

6.  Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients.

Authors:  Wai H Lim; Timothy H Mathew; John E Cooper; Scott Bowden; Graeme R Russ
Journal:  Nephrology (Carlton)       Date:  2003-12       Impact factor: 2.506

Review 7.  Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis.

Authors:  Martyn K White; Kamel Khalili
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

8.  Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

Authors:  Debra C Quenelle; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds.

Authors:  Dana Hocková; Antonín Holý; Milena Masojídková; Graciela Andrei; Robert Snoeck; Erik De Clercq; Jan Balzarini
Journal:  Bioorg Med Chem       Date:  2004-06-15       Impact factor: 3.641

Review 10.  New insights into progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710
View more
  5 in total

1.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.

Authors:  D Topalis; I Lebeau; M Krecmerová; G Andrei; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Anti-BK virus activity of nucleoside analogs.

Authors:  Parmjeet Randhawa; Jiri Zemlicka; Andreas Sauerbrei; Chris Meier; Karl Y Hostetler; James R Beadle; Noush Afarin Farasati; Yuchen Huang; Matthews Bradley
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

4.  Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.

Authors:  Sophie Duraffour; Robert Snoeck; Marcela Krecmerová; Joost van Den Oord; Rita De Vos; Antonín Holy; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

5.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.